Literature DB >> 3877472

Rett syndrome--an early catecholamine and indolamine deficient disorder?

Y Nomura, M Segawa, M Higurashi.   

Abstract

The results of clinical and polysomnographical examinations on 11 Japanese Rett syndrome cases were summarized to substantiate further our previous results regarding the pathophysiology of the disease. It was concluded that the disease starts early in infancy and takes a progressive course. Each characteristic symptom appears in an orderly sequence which is thought to reflect the sequential systemic involvement of certain neuronal systems. Based on the characteristic symptoms and signs, and polysomnographical studies, we speculated that the initial lesion was the locus coeruleus with a hypoactive noradrenergic system combined with other hypoactive monoaminergic systems, including those of serotonin and dopamine, occurring along with the early developmental course. In later stages, hyperfunction possibly due to postsynaptic supersensitivity of the dopamine system causes the characteristic symptoms of the Rett syndrome.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3877472     DOI: 10.1016/s0387-7604(85)80040-1

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  13 in total

1.  Describing the phenotype in Rett syndrome using a population database.

Authors:  L Colvin; S Fyfe; S Leonard; T Schiavello; C Ellaway; N De Klerk; J Christodoulou; M Msall; H Leonard
Journal:  Arch Dis Child       Date:  2003-01       Impact factor: 3.791

2.  The course of awake breathing disturbances across the lifespan in Rett syndrome.

Authors:  Daniel C Tarquinio; Wei Hou; Jeffrey L Neul; Gamze Kilic Berkmen; Jana Drummond; Elizabeth Aronoff; Jennifer Harris; Jane B Lane; Walter E Kaufmann; Kathleen J Motil; Daniel G Glaze; Steven A Skinner; Alan K Percy
Journal:  Brain Dev       Date:  2018-04-12       Impact factor: 1.961

Review 3.  Rett syndrome: a review of current knowledge.

Authors:  R Van Acker
Journal:  J Autism Dev Disord       Date:  1991-12

4.  The disruption of central CO2 chemosensitivity in a mouse model of Rett syndrome.

Authors:  Xiaoli Zhang; Junda Su; Ningren Cui; Hongyu Gai; Zhongying Wu; Chun Jiang
Journal:  Am J Physiol Cell Physiol       Date:  2011-02-09       Impact factor: 4.249

5.  Reduced cerebrospinal fluid B-endorphin levels in Rett syndrome.

Authors:  A R Genazzani; M Zappella; A Nalin; Y Hayek; F Facchinetti
Journal:  Childs Nerv Syst       Date:  1989-04       Impact factor: 1.475

6.  Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities.

Authors:  Rodney C Samaco; Caleigh Mandel-Brehm; Hsiao-Tuan Chao; Christopher S Ward; Sharyl L Fyffe-Maricich; Jun Ren; Keith Hyland; Christina Thaller; Stephen M Maricich; Peter Humphreys; John J Greer; Alan Percy; Daniel G Glaze; Huda Y Zoghbi; Jeffrey L Neul
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-09       Impact factor: 11.205

Review 7.  Breathing disorders in Rett syndrome: progressive neurochemical dysfunction in the respiratory network after birth.

Authors:  David M Katz; Mathias Dutschmann; Jan-Marino Ramirez; Gérard Hilaire
Journal:  Respir Physiol Neurobiol       Date:  2009-04-24       Impact factor: 1.931

8.  The trajectories of sleep disturbances in Rett syndrome.

Authors:  Kingsley Wong; Helen Leonard; Peter Jacoby; Carolyn Ellaway; Jenny Downs
Journal:  J Sleep Res       Date:  2014-09-14       Impact factor: 3.981

9.  Neurotrophic effects of Cerebrolysin in the Mecp2(308/Y) transgenic model of Rett syndrome.

Authors:  Edith Doppler; Edward Rockenstein; Kiren Ubhi; Chandra Inglis; Michael Mante; Anthony Adame; Leslie Crews; Monika Hitzl; Herbert Moessler; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2008-07-04       Impact factor: 17.088

10.  Sleep problems in Rett syndrome.

Authors:  Deidra Young; Lakshmi Nagarajan; Nick de Klerk; Peter Jacoby; Carolyn Ellaway; Helen Leonard
Journal:  Brain Dev       Date:  2007-05-24       Impact factor: 1.961

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.